EPO and Behcet disease: Recent randomized, placebo-controlled trials demonstrated that 8 weekly doses of erythropoietin (EPO) reduced cognitive dysfunction in patients with treatment-resistant depression (TRD)33 and in patients with BD in partial remission34.